Description: BioPharma Blog provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Shortly after Kyverna priced one of the sector’s largest IPOs in recent years, Maag spoke with BioPharma Blog about what it takes to go public now. Read more ➔
Small biotech Telomir Pharmaceuticals joined Kyverna and Metagenomi in going public this week, adding to the sector’s fastest start since 2021.
The company is one of just three preclinical biotechs to go public since last summer, but it raised significantly less than others that debuted with more advanced medicines.